Logo

Max Planck Institute Buys Cellomics ArrayScan Reader, Will Collaborate on High-Content Screening

Nov 02, 2005

NEW YORK, Nov. 2 (GenomeWeb News) - Cellomics will collaborate with Max Planck Institute in high-content screening development for drug discovery, Cellomics said last week.

 

As part of the agreement, the Max Planck Institute of Molecular Cell Biology and Genetics, located in Dresden, Germany, has purchased the Cellomics' ArrayScan VTI HCS Reader along with its complete portfolio of BioApplications and HCi informatics software.

 

The collaboration will include a mix of applications and new product development, as well as establishing a key demonstration center for Europe, said Daniel J. Calco, Cellomics' president, in a statement.

 

Cellomics, a unit of Fisher Biosciences, provides a cell-based platform.

Breaking News
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.